{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:21:00Z","timestamp":1790911260887,"version":"4.1.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"3","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,16]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Abnormalities involving class I HLA are frequent in many lymphoma subtypes but have not yet been extensively studied in cutaneous T-cell lymphomas (CTCLs). We characterized the occurrence of class I HLA abnormalities in 65 patients with advanced mycosis fungoides or S\u00e9zary syndrome. Targeted DNA sequencing, including coverage of HLA loci, revealed at least 1 HLA abnormality in 26 of 65 patients (40%). Twelve unique somatic HLA mutations were identified across 9 patients, and loss of heterozygosity or biallelic loss of HLA was found to affect 24 patients. Although specific HLA alleles were commonly disrupted, these events did not associate with a decrease in the total class I HLA expression. Genetic events preferentially disrupted HLA alleles capable of presenting greater numbers of putative neoantigens. HLA abnormalities co-occurred with other genetic immune evasion events and were associated with worse progression-free survival. Single-cell analyses demonstrated that HLA abnormalities were frequently subclonal. Through analysis of serial samples, we observed that disrupting class I HLA events change dynamically over the disease course. The dynamics of HLA disruption are highlighted in a patient who received pembrolizumab and in whom resistance to pembrolizumab was associated with the elimination of an HLA mutation. Overall, our findings show that genomic class I HLA abnormalities are common in advanced CTCL and may be an important consideration in understanding the effects of immunotherapy in CTCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024024817","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T16:54:56Z","timestamp":1728579296000},"page":"311-324","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Genetic alteration of class I HLA in cutaneous T-cell lymphoma"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3733-586X","authenticated-orcid":false,"given":"Alexa C.","family":"Kwang","sequence":"first","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2692-3906","authenticated-orcid":false,"given":"George E.","family":"Duran","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA"},{"name":"2Department of Dermatology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0428-0199","authenticated-orcid":false,"given":"Sebastian","family":"Fernandez-Pol","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Najidh","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufeng","family":"Li","sequence":"additional","affiliation":[{"name":"2Department of Dermatology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando N.","family":"Bastidas Torres","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica B.","family":"Wang","sequence":"additional","affiliation":[{"name":"2Department of Dermatology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3312-9156","authenticated-orcid":false,"given":"Melba","family":"Herrera","sequence":"additional","affiliation":[{"name":"2Department of Dermatology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0223-6537","authenticated-orcid":false,"given":"Tarek I.","family":"Bandali","sequence":"additional","affiliation":[{"name":"2Department of Dermatology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6382-4651","authenticated-orcid":false,"given":"David M.","family":"Kurtz","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2686-5873","authenticated-orcid":false,"given":"Youn H.","family":"Kim","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA"},{"name":"2Department of Dermatology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9061-7351","authenticated-orcid":false,"given":"Michael S.","family":"Khodadoust","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA"},{"name":"2Department of Dermatology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"23","key":"2025011616204007400_bib1","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025011616204007400_bib2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and Sezary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2025011616204007400_bib3","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1182\/bloodadvances.2022009575","article-title":"Treating relapsed\/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study","volume":"7","author":"Bachy","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025011616204007400_bib4","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1182\/blood-2023-188053","article-title":"Preliminary analysis demonstrates durvalumab (anti-PD-L1) & lenalidomide is superior to single-agent durvalumab (anti-PD-L1) in refractory\/advanced cutaneous T cell lymphoma in a randomized phase 2 trial","volume":"142","author":"Querfeld","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2025011616204007400_bib5","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"issue":"12","key":"2025011616204007400_bib6","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"issue":"4","key":"2025011616204007400_bib7","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2025011616204007400_bib8","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jid.2016.03.024","article-title":"Identification of gene mutations and fusion\u00a0genes in patients with Sezary syndrome","volume":"136","author":"Prasad","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"issue":"9","key":"2025011616204007400_bib9","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Ungewickell","year":"2015","journal-title":"Nat Genet"},{"issue":"12","key":"2025011616204007400_bib10","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet"},{"issue":"26","key":"2025011616204007400_bib11","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/blood-2016-02-699843","article-title":"Candidate driver genes involved in genome maintenance and DNA repair in Sezary syndrome","volume":"127","author":"Woollard","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2025011616204007400_bib12","doi-asserted-by":"crossref","first-page":"e1295202","DOI":"10.1080\/2162402X.2017.1295202","article-title":"HLA dependent immune escape mechanisms in B-cell lymphomas: implications for immune checkpoint inhibitor therapy?","volume":"6","author":"Nijland","year":"2017","journal-title":"OncoImmunology"},{"issue":"22","key":"2025011616204007400_bib13","doi-asserted-by":"crossref","first-page":"e2104504118","DOI":"10.1073\/pnas.2104504118","article-title":"Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma","volume":"118","author":"Fangazio","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2025011616204007400_bib14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"issue":"9","key":"2025011616204007400_bib15","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat Genet"},{"issue":"11","key":"2025011616204007400_bib16","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat Genet"},{"issue":"12","key":"2025011616204007400_bib17","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"33","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"issue":"12","key":"2025011616204007400_bib18","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/j.jid.2018.06.176","article-title":"An integrated data resource for genomic analysis of cutaneous T-cell lymphoma","volume":"138","author":"Chang","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"12","key":"2025011616204007400_bib19","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2017-02-768234","article-title":"Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E)","volume":"130","author":"Park","year":"2017","journal-title":"Blood"},{"issue":"17","key":"2025011616204007400_bib20","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.2019001744","article-title":"Targeted inhibition of CD47-SIRPalpha requires Fc-FcgammaR interactions to maximize activity in T-cell lymphomas","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2025011616204007400_bib21","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41467-024-45083-8","article-title":"MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides","volume":"15","author":"Chang","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"2025011616204007400_bib22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/bloodadvances.2018025114","article-title":"Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR","volume":"3","author":"Murray","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2025011616204007400_bib23","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/s41467-022-28799-3","article-title":"Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"2025011616204007400_bib24","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12943-021-01419-2","article-title":"Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma","volume":"20","author":"Rindler","year":"2021","journal-title":"Mol Cancer"},{"issue":"6","key":"2025011616204007400_bib25","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"8","key":"2025011616204007400_bib26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","article-title":"Strelka2: fast and accurate calling of germline and somatic variants","volume":"15","author":"Kim","year":"2018","journal-title":"Nat Methods"},{"key":"2025011616204007400_bib27","doi-asserted-by":"publisher","DOI":"10.1101\/861054","article-title":"Calling somatic SNVs and indels with Mutect2","author":"Benjamin","year":"2  2019","journal-title":"bioRxiv"},{"issue":"3","key":"2025011616204007400_bib28","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res"},{"issue":"16","key":"2025011616204007400_bib29","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"2025011616204007400_bib30","doi-asserted-by":"crossref","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing","volume":"12","author":"Talevich","year":"2016","journal-title":"PLoS Comput Biol"},{"issue":"5","key":"2025011616204007400_bib31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nmeth.3364","article-title":"MiXCR: software for comprehensive adaptive immunity profiling","volume":"12","author":"Bolotin","year":"2015","journal-title":"Nat Methods"},{"issue":"11","key":"2025011616204007400_bib32","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/nbt.3344","article-title":"Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes","volume":"33","author":"Shukla","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"23","key":"2025011616204007400_bib33","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","article-title":"OptiType: precision HLA typing from next-generation sequencing data","volume":"30","author":"Szolek","year":"2014","journal-title":"Bioinformatics"},{"issue":"12","key":"2025011616204007400_bib34","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1093\/bioinformatics\/btaa264","article-title":"scHLAcount: allele-specific HLA expression from single-cell gene expression data","volume":"36","author":"Darby","year":"2020","journal-title":"Bioinformatics"},{"issue":"D1","key":"2025011616204007400_bib35","first-page":"D948","article-title":"IPD-IMGT\/HLA database","volume":"48","author":"Robinson","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"2025011616204007400_bib36","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2025011616204007400_bib37","doi-asserted-by":"crossref","first-page":"2115197","DOI":"10.1080\/2162402X.2022.2115197","article-title":"Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sezary syndrome","volume":"11","author":"Su","year":"2022","journal-title":"OncoImmunology"},{"issue":"50","key":"2025011616204007400_bib38","doi-asserted-by":"crossref","first-page":"83294","DOI":"10.18632\/oncotarget.13065","article-title":"Mutations or copy number losses of CD58 and TP53 genes\u00a0in diffuse large B cell lymphoma are\u00a0independent unfavorable prognostic factors","volume":"7","author":"Cao","year":"2016","journal-title":"Oncotarget"},{"issue":"suppl 1","key":"2025011616204007400_bib39","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1182\/blood-2022-164603","article-title":"Comprehensive analysis of TP53 and CD58 mutations and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B cell lymphoma","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025011616204007400_bib40","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"2025011616204007400_bib41","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"issue":"12","key":"2025011616204007400_bib42","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov"},{"issue":"7","key":"2025011616204007400_bib43","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jid.2019.01.007","article-title":"Analysis of the tumor reactivity of tumor-infiltrating lymphocytes in a metastatic melanoma lesion that lost major histocompatibility complex class I expression after anti-PD-1 therapy","volume":"139","author":"Inozume","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"issue":"7","key":"2025011616204007400_bib44","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"issue":"19","key":"2025011616204007400_bib45","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2025011616204007400_bib46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2025011616204007400_bib47","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced beta2M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"44","key":"2025011616204007400_bib48","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.1038\/onc.2017.209","article-title":"Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers","volume":"36","author":"Liu","year":"2017","journal-title":"Oncogene"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/3\/311\/2351631\/blood_bld-2024-024817-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/3\/311\/2351631\/blood_bld-2024-024817-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T11:21:04Z","timestamp":1737026464000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/3\/311\/518151\/Genetic-alteration-of-class-I-HLA-in-cutaneous-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,1,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024817","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]}}}